Alerts in the last 24 hours

No Personalised Alerts!

To see personalised alerts you need to be logged in.

Log In

Merck KGaA Add to portfolio

DAXX:MRK, Jul 18, 08:54 UTC

Latest DAXX:MRK News

Filter your feed

Apply Filter

Thursday, July 12


News

Cue Biopharma Produces Immuno-STAT™ Biologic Candidate for Treatment of Autoimmune Disease Under Collaboration and License Agreement with Merck Nasdaq:CUE

MRK

CAMBRIDGE, Mass., July 12, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc., an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer and autoimmune diseases, today announced progress in its ongoing strategic collaboration with Merck (known as MSD outside of the United States and Canada) to develop Immuno-STATs™ for treating particular autoimmune diseases. Cue Biopharma has generated the first collaborative Immuno-STAT™ against an autoimmune disease target, establishing the end-date of Merck’s exclusivity period on Immuno-STATs™ in all areas of autoimmune disease (referred to as AI-STATs™) as no later than December 14, 2019. “We are targeting autoimmune diseases using two distinct mechanisms: (1) by delivery of inhibitory signals specifically to the disease-relevant autoreactive T cell compartment and; (2) by induction and expansion of regulatory T cells (Tregs), which subsequently may modulate a broad repertoire of self-reactive T cells. “We are very pleased with our progress to date and continue working closely with Merck towards the further development of our promising platform to realize the full potential of selective T cell modulation in the treatment of debilitating autoimmune diseases,” said Daniel Passeri, M.Sc., J.D., President and Chief Executive Officer of Cue Biopharma.

Read Full Details

Topics:
  • Business
  • Health
  • Technology
  • Financial

Friday, July 06


News

Dow 30 Stock Roundup: Bell-Boeing JV's Navy Deal Win, Merck Keytruda's Priority Review - July 6, 2018

MRK

A rally in tech shares helped the index rebound on Monday after initial hiccups on trade tensions. However, a tech selloff reversed early gains, leading to losses for the index on Tuesday. This led to major U.S. lenders announcing high dividend payouts and share buybacks, which saw bank shares rallying. However, a late session selloff in bank stocks led to markets shedding early gains. Tech stocks, which have rallied since 2017, also took a hit after Facebook, Inc. FB got embroiled in a data-misuse scandal. The Goldman Sachs Group, Inc. GS will be reviewing equity capital market transactions at its Australian branch after being accused of misleading potential investors in a block trade transaction that the unit had undertaken in relation to shares of Healthscope Limited in November 2015.

Read Full Details

Topics:
  • Business
  • Financial

Tuesday, July 03


News

Merck's Keytruda Gets Priority Review in Difficult Lung Cancer

MRK

At the recently concluded annual meeting of the American Society of Clinical Oncology, data presentation from this pivotal lung cancer study resulted in Merck emerging as a winner at this annual key cancer event. Data from the study showed that the combination of Keytruda plus chemotherapy led to significant improvement in both overall survival (OS) and progression-free survival regardless of PD-L1 expression. The PFS improvement or as we say reduction in the risk of progression or death was nearly half for patients in the Keytruda combination group compared with chemotherapy alone. In fact, Keytruda is the only anti-PD-1 approved in the first-line setting for certain lung cancer patients both as a monotherapy as well as a combination therapy with Eli Lilly’s LLY cancer drug, Alimta (pemetrexed) and carboplatin (pem/carbo).

Read Full Details

Topics:
  • Business
  • Health
News

Merck Launches Online Platform Fertility.com

MRK

Merck, a leading science and technology company, today announces the launch of the new online portal fertility.com. The Patient Support Portal (fertility.com/support) has been created to provide a profound source of information for women, men and couples who are trying or have been trying to conceive. The portal is designed to support patients at every step of their fertility journey, including educational materials that help them understand fertility and treatment options. This new online platform demonstrates Merck's commitment to continuing to support people trying to conceive, whilst also offering HCPs a scientific platform with the latest advances in reproductive medicine.

Read Full Details

Topics:
  • Business
  • Health
  • Technology
  • Science
News

Germany's Merck sees performance materials unit turning corner in 2020

MRK

U.S. Germany's Merck sees performance materials unit turning corner in 2020. (Reuters) - Germany's Merck KGaA (MRCG.DE) said it expects its performance materials business to return to sales and earnings growth after next year as it tackles tough competition from Chinese rivals in the market for liquid crystals for flat-screen televisions. Average annual sales for the performance materials business are expected to grow by between 2 and 3 percent the year after next, said Merck, the world's leading supplier of liquid crystals ahead of Japan's JNC Corp and DIC Corp (4631.T). The division said that growth in sales to the chip sector, from coatings, OLED (organic light-emitting diode) materials and light-sensitive materials would more than compensate for the decline in revenue from liquid crystals for displays after 2019.

Read Full Details

Topics:
  • Business
  • Financial
News

Merck KGaA sees Performance Materials returning to growth after 2019

MRK

Merck KGaA sees Performance Materials returning to growth after 2019. ReutersJuly 3, 2018, 5:24 AM GMT. FRANKFURT (Reuters) - Germany's Merck KGaA (MRCG.DE) said it aimed to return to earnings growth its Performance Materials business, which makes liquid crystals for flat-screen TVs, after next year as it tackles tough competition from Chinese rivals. In the long run, the unit sees its average annual margin on earnings before interest, tax, depreciation, amortisation (EBITDA) and one-offs coming to around 30 percent, Merck said in a statement on Tuesday. What to read next.

Read Full Details

Topics:
  • Business
  • Financial

Monday, July 02


News

Merck Launches Two New Technologies for Improved Efficiency in Fertility Labs

MRK

Merck, a leading science and technology company, today announces the launch of QBOX IVF, and the new Geri® Assess 2.0, in its continued drive to serve the needs of its customers and to become the preferred treatment partner for all IVF stakeholders and assisted reproductive treatment (ART) clinics. Setting a strong basis for connectivity in the ART clinic, Merck introduces QBOX IVF, a hub that enables two-way unidirectional automated information transfer between Merck's clinic devices Gidget® and Geri® Connect & Assess (including Geri® Assess 2.0 and Eeva®) and industry-leading Electronic Medical Record (EMR) providers, thus improving standardization and automation. In addition, Merck and Genea Biomedx, Australia, through their joint development hub ARTinnovations, developed a new module that extends the embryo assessment offering within the Geri® Connect & Assess platform. While Geri® Assess 1.0 provided user defined scoring systems to assess and grade embryos, Geri® Assess 2.0 provides automated cell event tracking using latest Artificial Intelligence (AI) technology and even allows for custom applied scoring algorithms for embryo assessment and grading. The new module helps clinics simplify embryo assessment, improve consistency across users and reduce the time spent in annotations by automatically detecting key events in embryo and blastocyst development.

Read Full Details

Topics:
  • Business
  • Health
  • Technology
  • Science
News

Merck Launches Two New Technologies for Improved Efficiency in Fertility Labs

MRK

Merck, a leading science and technology company, today announces the launch of QBOX IVF, and the new Geri® Assess 2.0, in its continued drive to serve the needs of its customers and to become the preferred treatment partner for all IVF stakeholders and assisted reproductive treatment (ART) clinics. Setting a strong basis for connectivity in the ART clinic, Merck introduces QBOX IVF, a hub that enables two-way unidirectional automated information transfer between Merck's clinic devices Gidget® and Geri® Connect & Assess (including Geri® Assess 2.0 and Eeva®) and industry-leading Electronic Medical Record (EMR) providers, thus improving standardization and automation. In addition, Merck and Genea Biomedx, Australia, through their joint development hub ARTinnovations, developed a new module that extends the embryo assessment offering within the Geri® Connect & Assess platform. While Geri® Assess 1.0 provided user defined scoring systems to assess and grade embryos, Geri® Assess 2.0 provides automated cell event tracking using latest Artificial Intelligence (AI) technology and even allows for custom applied scoring algorithms for embryo assessment and grading. The new module helps clinics simplify embryo assessment, improve consistency across users and reduce the time spent in annotations by automatically detecting key events in embryo and blastocyst development.

Read Full Details

Topics:
  • Business
  • Health
  • Technology
  • Science
News

Merck Launches Two New Technologies for Improved Efficiency in Fertility Labs

MRK

Merck, a leading science and technology company, today announces the launch of QBOX IVF, and the new Geri® Assess 2.0, in its continued drive to serve the needs of its customers and to become the preferred treatment partner for all IVF stakeholders and assisted reproductive treatment (ART) clinics. Setting a strong basis for connectivity in the ART clinic, Merck introduces QBOX IVF, a hub that enables two-way unidirectional automated information transfer between Merck's clinic devices Gidget® and Geri® Connect & Assess (including Geri® Assess 2.0 and Eeva®) and industry-leading Electronic Medical Record (EMR) providers, thus improving standardization and automation. In addition, Merck and Genea Biomedx, Australia, through their joint development hub ARTinnovations, developed a new module that extends the embryo assessment offering within the Geri® Connect & Assess platform. While Geri® Assess 1.0 provided user defined scoring systems to assess and grade embryos, Geri® Assess 2.0 provides automated cell event tracking using latest Artificial Intelligence (AI) technology and even allows for custom applied scoring algorithms for embryo assessment and grading. The new module helps clinics simplify embryo assessment, improve consistency across users and reduce the time spent in annotations by automatically detecting key events in embryo and blastocyst development.

Read Full Details

Topics:
  • Business
  • Health
  • Technology
  • Science
News

Merck to Present New Data from Studies of Investigational HIV Therapy Doravirine, Including Pivotal DRIVE-FORWARD Trial, at AIDS 2018

MRK

“While enormous progress has been made in the fight against HIV/AIDS, continued scientific innovation is needed given the unmet need that continues to exist in HIV,” said Dr. George Hanna, vice president and therapeutic area head of infectious diseases, global clinical development, Merck Research Laboratories. Late-breaking Poster Exhibition: Wednesday, July 25, 12:30-14:30 CET, Poster Exhibition Area, Hall 1. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola. For more information, visit www.merck.com and connect with us on Twitter, Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USAThis news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Read Full Details

Topics:
  • Business
  • Health